Clinical Study

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In Pd L1?Selected Patients With Completely Resected S

Posted Date: May 14, 2018

  • Investigator: John Morris
  • Specialties: Hematology/Oncology, Oncology, Cancer, Lung Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is an antibody that affects your immune system by blocking the programmed death?ligand 1 (PD L1) pathway. The PD L1 pathway is involved in decreasing your body’s natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help your immune system stop or reverse the growth of tumors.

Criteria:

To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer

Keywords:

Go29527, Cancer, Resected Nsclc, Lung

For More Information:

Uc Cancer Institute
5135847698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.